OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

First clinical trial to test the safety and efficacy of a novel first-in-class targeted therapy (small-molecule prodrug) that selectively releases a potent DNA alkylating agent for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, April 18, 2018 /PRNewswire/ — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. […]

HOMEWhat’s NewNewsOBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2018.Jan.17

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

2018.Jul.08

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)